

### **Evaluation Report for Category L, Subcategory 1.1 Application**

**Application Number:** 2019-0420

**Application:** Submissions subject to Protection of Proprietary Interests in

Pesticide Data Policy-Equivalency/Data Compensation Assessment

**Product:** Nufarm Clodinafop-Propargyl Technical

**Registration Number:** #####

Active ingredient (a.i.): Clodinafop-propargyl

PMRA Document Number: 3095675

### **Purpose of Application**

The purpose of this application was to register a new technical grade product containing clodinafop-propargyl, based on a registered precedent product.

#### **Chemistry Assessment**

Common Name: Clodinafop-propargyl

IUPAC\* Chemical Name: prop-2-ynyl (*R*)-2-[4-(5-chloro-3-fluoro-2-

pyridyloxy)phenoxy]propionate

CAS† Chemical Name: 2-propynyl (2*R*)-2-[4-[(5-chloro-3-fluoro-2-

pyridinyl)oxylphenoxylpropanoate

Nufarm Clodinafop-Propargyl Technical has the following properties:

Property	Result
Colour and physical state	Off-white
Nominal concentration	97.47%
Odour	Characteristic odour
Density	1.3797 g/mL
Vapour pressure	3.80 × 10 <sup>-6</sup> Pa
рН	5.43 (1% w/v) at 25°C
Solubility in water	$3.17 \times 10^{-3}$ g/L at pH = 4 $2.96 \times 10^{-3}$ g/L at pH = 7



<sup>\*</sup> International Union of Pure and Applied Chemistry

<sup>†</sup> Chemical Abstracts Service

Property	Result
n-Octanol/water partition coefficient	$\log K_{ow} = 3.61$

The required chemistry data for Nufarm Clodinafop-Propargyl Technical have been provided, reviewed, and found to be acceptable.

# Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

#### Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found it sufficient to support the registration of Nufarm Clodinafop-Propargyl Technical.

# References

<b>PMRA</b>	
<b>Document</b>	
Number	Reference
2956841	2017, Clodinafop-propargyl Technical Synthesis Process, DACO:
	2.11,2.11.1,2.11.2,2.11.3,2.11.4 CBI
2956843	2016, Qualitative and Quantitative Profile of the test substance Clodinafop-
	propargyl 96% Technical (Five Batch Analysis), DACO: 2.13.2,2.13.3 CBI
2956844	2017, Determination of Colour of Clodinafop-propargyl 96% TC, DACO: 2.14.1 CBI
2956845	2017, Determination of Physical State of Clodinafop-propargyl 96% TC, DACO:
	2.14.2 CBI
2956846	2017, Determination of Odour of Clodinafop-propargyl 96% TC, DACO: 2.14.3
	CBI
2956847	2017, Determination of Melting Point/Melting Range of Clodinafop-propargyl
2056040	96% TC, DACO: 2.14.4 CBI
2956848	2017, Determination of Density and Specific Gravity of Clodinafop-propargyl
2056940	96% TC, DACO: 2.14.6 CBI
2956849	2017, Determination of Solubility of Clodinafop-propargyl 96% TC in Water, DACO: 2.14.7 CBI
2956850	2017, Determination of Solubility of Clodinafop-propargyl 96% TC, DACO:
2730030	2.14.8 CBI
2956851	2017, Determination of Vapour Pressure of Clodinafop-propargyl 96% TC,
_,_,_,	DACO: 2.14.9 CBI
2956852	2017, Determination of Dissociation Contstant of Clodinafop-propargyl 96% TC,
	DACO: 2.14.10 CBI
2956853	2017, Determination of Partition Coefficient of Clodinafop-propargyl 96% TC,
	DACO: 2.14.11 CBI
2956854	2017, Determination of UV-Visible Spectrum of Clodinafop-propargyl 96% TC,
	DACO: 2.14.12 CBI
2956855	2017, Determination of Accelerated Storage Stability of Clodinafop-propargyl
2017167	96% TC with Packaging Material, DACO: 2.14.13,2.14.14 CBI
3045465	2019, Qualitative and Quantitative Profile of the test substance Clodinafop-
2004002	Propargyl 96% Technical (Five Batch Analysis) FINAL, DACO: 2.13.4 CBI
3084003	2017, Determination of pH of Clodinafop-propargyl 96% TC, DACO:
	2.14.15,830.7000 CBI

ISSN: 1911-8082

#### © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2020

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.